Elbit Imaging Reports Wider Q3 Loss Vs. Year Ago

Elbit Imaging Reports Wider Q3 Loss Vs. Year Ago

Elbit Imaging fell 1.4% in Friday’s afternoon trade after the company said that for Q3, its loss widened from the prior year period even as revenue rose 42.5% year-over-year. The real estate company posted a Q3 net loss of ILS35.6 million or about $9.3 million, widening from the prior-year period’s loss of ILS2.4 million. Revenue was ILS44.6 million, up from ILS31.3 million in the same quarter last year.

Read More ˃
Wall Street Sees Higher Open on Soaring Oil Prices

Wall Street Sees Higher Open on Soaring Oil Prices

U.S. stocks were pointing to a moderately higher open on Wednesday, led by gains in the energy sector, amid growing optimism that major oil producers were closing in on a deal to curb production at a meeting in Vienna, and as the U.S. economy saw a major jump in job creation. Oil prices surged with global benchmark Brent Crude up 7.85% recently and U.S. benchmark West Texas Intermediate up 7.30% […]

Read More ˃
Prima BioMed, WuXi Biologics Enter Strategic Euologics Development, Manufacturing Partnership

Prima BioMed, WuXi Biologics Enter Strategic Euologics Development, Manufacturing Partnership

Prima BioMed Ltd (PBMD), said Wednesday that it has signed a non-binding memorandum of understanding with WuXi Biologics, an open-access R&D capability and technology platform company, to form a strategic biologics development and manufacturing partnership. Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong where rights are retained by Prima’s […]

Read More ˃
ImmunoCellular Therapeutics Reports Updated Data from Two Trials

ImmunoCellular Therapeutics Reports Updated Data from Two Trials

ImmunoCellular Therapeutics, a clinical-stage biotechnology company, reported Monday updated immune monitoring data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma and updated long-term survival data from the phase 1 trial of ICT-107. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Glioblastoma is the most common and most aggressive cancer that begins within the brain. The updated immune response data […]

Read More ˃
Greatbatch Medical Informs Customers Its Standard Offset Cup Impactor Must Be Wrapped for Sterilization

Greatbatch Medical Informs Customers Its Standard Offset Cup Impactor Must Be Wrapped for Sterilization

Greatbatch Medical, held by Integer Holdings, told its distributors and customers by overnight mail that the Standard Offset Cup Impactor with POM-C Handle grip should be individually wrapped during sterilization processing. The device failed sterility testing when housed in a dedicated instrument case using the IFU recommended sterilization procedures, the company said on Wednesday, adding the dedicated instrument case is not manufactured by Greatbatch Medical. The company said an internal […]

Read More ˃